首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Pharmacokinetics of Gatifloxacin and Interaction with an Antacid Containing Aluminum and Magnesium
【2h】

Pharmacokinetics of Gatifloxacin and Interaction with an Antacid Containing Aluminum and Magnesium

机译:加替沙星的药代动力学及其与含铝和镁的抗酸剂的相互作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The pharmacokinetics of gatifloxacin (400 mg orally) and the influence of the antacid aluminum magnesium hydroxide (20 ml of Maalox 70) on the bioavailability of gatifloxacin in 24 healthy volunteers were assessed. In an open, randomized, six-period crossover study, the volunteers received either gatifloxacin alone (treatments A and D); aluminum magnesium hydroxide concomitant with gatifloxacin (treatment C); or aluminum magnesium hydroxide 2 h before (treatment B), 2 h after (treatment E), or 4 h after gatifloxacin administration (treatment F). Gatifloxacin concentrations were measured by a validated bioassay and high-performance liquid chromatography. Pharmacokinetics of a single 400-mg dose of gatifloxacin alone were characterized as follows (mean ± standard deviation): peak concentration (Cmax), 3.8 ± 0.5 (treatment A) and 3.4 ± 0.9 (treatment D) μg/ml; time to Cmax, 1.4 ± 0.8 (treatment A) and 1.7 ± 0.7 (treatment D) h; area under the curve from time zero to infinity (AUC0–∞), 33.5 ± 5.9 (treatment A) and 31.4 ± 3.4 (treatment D) μg · h/ml; urine recovery, (83 ± 6)% (treatment A) and (84 ± 8)% (treatment D). Comparison of the results obtained by bioassay showed a good correlation. Aluminum magnesium hydroxide administration 2 h before (treatment B) or concomitant with (treatment C) gatifloxacin decreased the Cmax by 45% (2.1 ± 1.2 μg/ml) or even 68% (1.2 ± 0.4 μg/ml) highly significantly (P < 0.01). AUC0–∞ was significantly reduced from 33.5 ± 5.9 to 19.4 ± 6.9 μg · h/ml (by 42%) or even to 11.9 ± 3.3 μg · h/ml (by 64%) (P < 0.01). If aluminum magnesium hydroxide was given 2 h after gatifloxacin (treatment E), there was no significant reduction of concentration in serum but AUC0–∞ was significantly reduced from 31.4 ± 3.4 to 25.9 ± 5.3 μg · h/ml (18%) (P < 0.01). Aluminum magnesium hydroxide given 4 h after gatifloxacin (treatment F) showed no influence on the gatifloxacin pharmacokinetics. Therefore, the optimal time between gatifloxacin application and the intake of an aluminum-containing antacid should be 4 h.
机译:评估了加替沙星(400 mg口服)的药代动力学以及抗酸铝氢氧化镁(20 ml Maalox 70)对加替沙星在24名健康志愿者中生物利用度的影响。在一项开放,随机,六期交叉研究中,志愿者分别接受加替沙星治疗(治疗A和D);氢氧化铝镁与加替沙星相伴(治疗C);或在加替沙星治疗前2小时(治疗B),治疗2小时后(治疗E)或4小时后氢氧化铝镁(治疗F)。加替沙星浓度是通过经过验证的生物测定和高效液相色谱法测量的。单独使用400 mg加替沙星的单剂量药代动力学的特征如下(平均值±标准差):峰值浓度(Cmax),3.8±0.5(治疗A)和3.4±0.9(治疗D)μg/ ml;达到Cmax的时间为1.4±0.8(处理A)和1.7±0.7(处理D)h;从零到无穷大的曲线下面积(AUC0–∞),33.5±5.9(处理A)和31.4±3.4(处理D)μg·h / ml;尿液回收率(83±6)%(治疗A)和(84±8)%(治疗D)。通过生物测定获得的结果的比较显示出良好的相关性。 (治疗B)前2小时或与(治疗C)加替沙星同时使用氢氧化铝镁可显着降低Cmax 45%(2.1±1.2μg/ ml)甚至68%(1.2±0.4μg/ ml)(P < 0.01)。 AUC0-∞从33.5±5.9降低到19.4±6.9μg·h / ml(降低42%),甚至降低到11.9±3.3μg·h / ml(降低64%)(P <0.01)。如果加替沙星治疗2小时后给予氢氧化铝镁(治疗E),则血清中浓度没有明显降低,但AUC0–∞从31.4±3.4显着降低至25.9±5.3μg·h / ml(18%)(P <0.01)。加替沙星(治疗F)后4小时给予氢氧化铝镁对加替沙星药代动力学没有影响。因此,加替沙星应用与摄入含铝抗酸药之间的最佳时间应为4小时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号